Emlino

Empagliflozin & Linagliptin

DIABETES

INDICATION

Emlino (Empagliflozin and Linagliptin) is indicated for use in combination with metformin as an adjunct to diet and exercise, to achieve glycemic control in adult patients with type 2 diabetes mellitus (T2DM) who are:

• inadequately controlled on metformin and empagliflozin, or

• inadequately controlled on metformin and linagliptin or

• already controlled with the free combination of metformin, empagliflozin, and linagliptin.

DOSAGE AND ADMINISTRATION

Route of administration: Oral.

For patients with T2DM inadequately controlled on:

• metformin and linagliptin 5 mg, the recommended dose of Emlino\\\\\\\\r\\\\\\\\nis empagliflozin 10 mg/linagliptin 5 mg, once daily.

• metformin and empagliflozin 10 mg, the recommended dose of\\\\\\\\r\\\\\\\\nEmlino is empagliflozin 10 mg/linagliptin 5 mg, once daily.

• metformin and empagliflozin 25 mg, the recommended dose of\\\\\\\\r\\\\\\\\nEmlino is empagliflozin 25 mg/linagliptin 5 mg, once daily. Emlino can be taken with or\\\\\\\\r\\\\\\\\nwithout food and at any time of day, preferably at the same time of the day.

OR, AS DIRECTED BY PHYSICIAN.

COMPOSITION

Emlino 10/5: Each box contains 2×10 tablets in Alu-Alu blisterstrips.

Emlino 25/5: Each boxcontains 1×10 tablets in Alu-Alu blister strips.